Radiofrequency Ablation of Metastatic Pheochromocytoma

Overview

Journal J Vasc Interv Radiol

Specialties Cardiology & Vascular Diseases
Radiology

Date 2009 Oct 31

PMID 19875067

Citations 16

Authors

Aradhana M Venkatesan

Julia Locklin

Edwin W Lai

Karen T Adams

Antonio Tito Fojo

Karel Pacak

Bradford J Wood

Affiliations

Soon will be listed here.

Abstract

In the present report on the preliminary safety and effectiveness of radiofrequency (RF) ablation for pheochromocytoma metastases, seven metastases were treated in six patients (mean size, 3.4 cm; range, 2.2-6 cm). alpha- and beta-adrenergic and catecholamine synthesis inhibition and intraprocedural anesthesia monitoring were used. Safety was assessed by recording ablation-related complications. Complete ablation was defined as a lack of enhancement within the ablation zone on follow-up computed tomography. No serious adverse sequelae were observed. Complete ablation was achieved in six of seven metastases (mean follow-up, 12.3 months; range, 2.5-28 months). In conclusion, RF ablation may be safely performed for metastatic pheochromocytoma given careful attention to peri-procedural management.

Citing Articles

Partial biochemical response of adrenal artery embolization for pheochromocytoma: A case report and review of the literature.

Choque-Chavez F, Paez-Carpio A, Mora M, Montserrat S, Pascagaza A, Burrel M Radiol Case Rep. 2024; 20(2):924-928.

PMID: 39654570 PMC: 11625116. DOI: 10.1016/j.radcr.2024.10.107.

International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents.

Casey R, Hendriks E, Deal C, Waguespack S, Wiegering V, Redlich A Nat Rev Endocrinol. 2024; 20(12):729-748.

PMID: 39147856 DOI: 10.1038/s41574-024-01024-5.

Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.

Taieb D, Nolting S, Perrier N, Fassnacht M, Carrasquillo J, Grossman A Nat Rev Endocrinol. 2023; 20(3):168-184.

PMID: 38097671 DOI: 10.1038/s41574-023-00926-0.

Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.

Gabiache G, Zadro C, Rozenblum L, Vezzosi D, Mouly C, Thoulouzan M Cancers (Basel). 2023; 15(18).

PMID: 37760633 PMC: 10526298. DOI: 10.3390/cancers15184666.

Locoregional Thermal and Chemical Tumor Ablation: Review of Clinical Applications and Potential Opportunities for Use in Low- and Middle-Income Countries.

Quang T, Yang J, Mikhail A, Wood B, Ramanujam N, Mueller J JCO Glob Oncol. 2023; 9:e2300155.

PMID: 37625104 PMC: 10581629. DOI: 10.1200/GO.23.00155.

References

Rosenthal D, Hornicek F, Wolfe M, Jennings L, Gebhardt M, Mankin H . Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment. J Bone Joint Surg Am. 1998; 80(6):815-21. DOI: 10.2106/00004623-199806000-00005. View

Lo W, vanSonnenberg E, Shankar S, Morrison P, Silverman S, Tuncali K . Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session. J Vasc Interv Radiol. 2006; 17(1):175-9. DOI: 10.1097/01.rvi.0000188748.51764.ce. View

Onik G, Onik C, Medary I, Berridge D, Chicks D, Proctor L . Life-threatening hypertensive crises in two patients undergoing hepatic radiofrequency ablation. AJR Am J Roentgenol. 2003; 181(2):495-7. DOI: 10.2214/ajr.181.2.1810495. View

Chini E, Brown M, Farrell M, Charboneau J . Hypertensive crisis in a patient undergoing percutaneous radiofrequency ablation of an adrenal mass under general anesthesia. Anesth Analg. 2004; 99(6):1867-1869. DOI: 10.1213/01.ANE.0000136803.54212.E1. View

Wood B, Abraham J, Hvizda J, Alexander H, Fojo T . Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003; 97(3):554-60. PMC: 2443414. DOI: 10.1002/cncr.11084. View

Goldstein R, ONEILL Jr J, Holcomb 3rd G, Morgan 3rd W, Neblett 3rd W, OATES J . Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999; 229(6):755-64; discussion 764-6. PMC: 1420821. DOI: 10.1097/00000658-199906000-00001. View

John H, ZIEGLER W, Hauri D, Jaeger P . Pheochromocytomas: can malignant potential be predicted?. Urology. 1999; 53(4):679-83. DOI: 10.1016/s0090-4295(98)00612-8. View

Mayo-Smith W, Dupuy D . Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results. Radiology. 2004; 231(1):225-30. DOI: 10.1148/radiol.2311031007. View

Eisenhofer G, Bornstein S, Brouwers F, Cheung N, Dahia P, de Krijger R . Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004; 11(3):423-36. DOI: 10.1677/erc.1.00829. View

10.

Eisenhofer G, Rivers G, Rosas A, Quezado Z, Manger W, Pacak K . Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf. 2007; 30(11):1031-62. DOI: 10.2165/00002018-200730110-00004. View

11.

Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J . Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest. 1992; 15(9):631-42. DOI: 10.1007/BF03345807. View

12.

Rhim H, Goldberg S, Dodd 3rd G, Solbiati L, Lim H, Tonolini M . Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. Radiographics. 2001; 21 Spec No:S17-35; discussion S36-9. DOI: 10.1148/radiographics.21.suppl_1.g01oc11s17. View

13.

Perry R, KEISER H, Norton J, Wall R, Robertson C, Travis W . Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg. 1990; 212(5):621-8. PMC: 1358191. DOI: 10.1097/00000658-199011000-00010. View

14.

Steinsapir J, CARR A, Prisant L, BRANSOME Jr E . Metyrosine and pheochromocytoma. Arch Intern Med. 1997; 157(8):901-6. View

15.

Reisch N, Peczkowska M, Januszewicz A, Neumann H . Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens. 2006; 24(12):2331-9. DOI: 10.1097/01.hjh.0000251887.01885.54. View

16.

Eisenhofer G, Goldstein D, Stull R, KEISER H, Sunderland T, Murphy D . Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem. 1986; 32(11):2030-3. View

17.

Sacks D, McClenny T, Cardella J, Lewis C . Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003; 14(9 Pt 2):S199-202. DOI: 10.1097/01.rvi.0000094584.83406.3e. View

18.

Mantero F, Terzolo M, Arnaldi G, Osella G, Masini A, Ali A . A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000; 85(2):637-44. DOI: 10.1210/jcem.85.2.6372. View

19.

Mamlouk M, vanSonnenberg E, Stringfellow G, Smith D, Wendt A . Radiofrequency ablation and biopsy of metastatic pheochromocytoma: emphasizing safety issues and dangers. J Vasc Interv Radiol. 2009; 20(5):670-3. DOI: 10.1016/j.jvir.2009.01.031. View

20.

Lenders J, Eisenhofer G, Mannelli M, Pacak K . Phaeochromocytoma. Lancet. 2005; 366(9486):665-75. DOI: 10.1016/S0140-6736(05)67139-5. View